SCHEMBL1966595

SCHEMBL1966595

Cc1cccc(-n2cccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.56
ACHE P22303 1/20 0.50
HSP90AA1 P07900 1/20 0.50
MGLL Q99685 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 5/20 0.47
HPGD P15428 1/20 0.47
ADRB1 P08588 1/20 0.47
KDM4E B2RXH2 1/20 0.44
AOC2 O75106 1/20 0.43
ALOX5 P09917 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KCNH2 Q12809 1/20 0.42
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
CASP6 P55212 1/20 0.41
KMT2A Q03164 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20319187 0.82 MAPT (0.68) MAPTMGLLL3MBTL1ALDH1A1HPGD
SCHEMBL10053917 0.77 HSP90AA1 (0.47) MAPTACHEHSP90AA1MGLLL3MBTL1
SCHEMBL5604589 0.77 MAPT (0.44) MAPTACHEHSP90AA1L3MBTL1ALDH1A1
SCHEMBL26569849 0.77 MAPT (0.39) MAPTHSP90AA1L3MBTL1ALDH1A1HPGD
SCHEMBL872242 0.76 IDO1 (0.64) MAPTMEN1KMT2A
Ammonia Solution, Strong SCHEMBL10510986 0.74 IDO1 (0.62) MAPTMEN1KMT2A
SCHEMBL28273980 0.73 ACHE (0.52) MAPTACHEHSP90AA1MGLLL3MBTL1
SCHEMBL2091295 0.73 MGLL (0.53) MAPTACHEMGLLALDH1A1ADRB1
SCHEMBL6535778 0.73 HSP90AA1 (0.52) MAPTHSP90AA1MGLLL3MBTL1ALDH1A1
SCHEMBL1366622 0.72 L3MBTL1 (0.56) MAPTACHEL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US claimed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US claimed
EP-4185564-A1 TRICYCLIC HETEROCYCLES Merck Patent GmbH (DE) 2023-05-31 EP claimed
CN-115948751-A Ring-opening dihydroalkoxylation reaction method of electrocatalytic N-aryl maleimide and alcohol 广西师范大学 2023-04-11 CN claimed
EP-4146652-A1 TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS Merck Patent GmbH (DE) 2023-03-15 EP claimed
WO-2021224291-A1 TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS MERCK PATENT GMBH (DE) 2021-11-11 WO claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-5415893-A Dispersion of electrically conductive particles in a dispersing medium DSM N.V. (NL) 1995-05-16 US claimed
EP-4157844-B1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-07-10 EP disclosed
EP-4334319-A1 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER Merck Patent GmbH (DE) 2024-03-13 EP disclosed
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US disclosed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US disclosed
EP-0424048-A2 Electrically conductive pigmentary composites KERR-McGEE CHEMICAL CORPORATION (US) 1991-04-24 EP disclosed
US-4795687-A POLYTHIENYLENE, POLYPRYRROLE OR POLYANILINE MATERIAL PREPARED BY OXIDATION POLYMERIZATION MITSUBISHI KASEI CORP. (JP) 1989-01-03 US disclosed
EP-0261837-A2 Electrically conductive material and a process for the preparation of same and secondary battery using the electrically conductive material Sanyo Electric Co., Ltd (JP) 1988-03-30 EP disclosed
US-4731311-A Electrically conductive material and secondary battery using the electrically conductive material SANYO ELECTRIC CO., LTD. (JP) 1988-03-15 US disclosed
EP-0219063-A2 Process of manufacturing an electrically conductive material and a secondary battery using the electrically conductive material Sanyo Electric Co., Ltd (JP) 1987-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 MAPT 2472/4885ACHE 4878/4885HSP90AA1 584/4885
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 MAPT 4504/4885ACHE 572/4885HSP90AA1 3007/4885
US-20230174538-A1 Tricyclic heterocycles YAP1, TEAD1, TERF2IP MAPT 2572/4885ACHE 4874/4885HSP90AA1 594/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 MAPT 4244/4885ACHE 715/4885HSP90AA1 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.